The makers of Xarelto have not bridled their efforts to increase sales of the new-generation blood thinner because thousands of U.S. law firms have amped up theirs to solicit clients who were allegedly injured by the drug. They have done the opposite, according to recent reports, as they prepare to launch studies geared towards expanding its range of approved uses.
An article on August 29th from ThePharmaLetter.com indicates that Bayer Healthcare and Janssen Research & Development have announced their launch of three studies that will look at the safety and effectiveness of Xarelto, known its generic form as rivaroxaban, for use in patients who suffered an embolic stroke for an undetermined source, patients with peripheral artery disease (PAD) undergoing peripheral artery interventions, and for use in acute coronary syndrome (ACS).
Xarelto was originally approved by the U.S. Food and Drug Administration (FDA) in July 2011 to prevent the risk of blood clots, pulmonary embolism and deep vein thrombosis in individuals who underwent a hip or knee replacement surgery. Later that year, Xarelto was cleared to treat individuals with atrial fibrillation who may be at an increased risk for stroke.
Since then, the FDA’s database of adverse event reports shows thousands of complaints filed over the anticoagulant, which has become one of the latest medications targeted by plaintiffs’ law firms in the U.S. Recent data shows that firms throughout the country together spent $1.2 million on spending to target clients for Xarelto lawsuit claims alleging internal bleeding and other injuries.
Despite this recent buzz about Xarelto, Bayer and Janssen, who jointly market Xarelto, maintain their commitment to expand its uses, to benefit a greater number of patients. “Together with our partner Janssen, we are committed to further investigate the potential benefits of rivaroxaban in areas of significant unmet medical need,” a member of Bayer’s executive committee and head of global development said in a statement.
The companies don’t plan to stop there, though. “Areas of unmet medical need still exist where rivaroxaban could potentially benefit even more patients at risk of the serious and often life-threatening diseases caused by blood clots,” the company maintains.